Investing Ideas
/
Slovenian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Slovenian Pharmaceuticals & Biotech Undervalued over 20% based on DCF

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.

1 companies

Krka d. d

Market Cap: €6.0b

A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.

KRKG

€200.00

49.3%